Dermatitis herpetiformis in a patient receiving infliximab for ankylosing spondylitis [9]

European Journal of Dermatology

Volumn 18, Issue 1, 2008, Pages 88-89

  Sonmezoglu Marakli, Selma ^a   Uzun, Soner ^a   Ozbek, Suleyman ^a   Tuncer, Ilhan ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; INFLIXIMAB;

ADULT; ANKYLOSING SPONDYLITIS; CASE REPORT; DERMATITIS HERPETIFORMIS; DRUG WITHDRAWAL; GLUTEN FREE DIET; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; MALE; REMISSION;

ADULT; ANTIBODIES, MONOCLONAL; DERMATITIS HERPETIFORMIS; HUMANS; MALE; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38549120275     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Winterfield LS, Menter A. Infliximab. Dermatol Ther 2004; 17: 409-26.
2. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007; 156: 486-91.
3. Fry L. Dermatitis herpetiformis: problems, progress and prospects. Eur J Dermatol 2002; 12: 523-31.
4. Humbert P. Pelletier F, Dreno B, Puzenat E, Aubin F. Gluten intolerance and skin diseases. Eur J Dermatol 2006; 16: 4-11.
5. Amerio P, Verdolini R, Giangiacomi M, Proietto G, Feliciani C, Offidani A,Bossi G. Expression of eotaxin, interleukin 13 and tumour necrosis factor-alpha in dermatitis herpetiformis.Br J Dermatol 2000; 143: 974-8.
6. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005; 52: 2513-8.